The evolution of enabling technologies and their associated perspectives into molecular mechanisms underlying disease has extended beyond the abilities of scientific and clinical structures to advance their translation into new algorithms that improve the health of patients and populations.1 Research programs have yielded a vast array of novel molecules related to pathophysiological mechanisms that represent diagnostic and therapeutic targets which have the potential for personalized healthcare management. Yet, despite extraordinary scientific advances, routine successful translation of discovery into new therapeutic tools remains a distant vision. Beyond constraints in bridging discovery science with clinical translation due to obstacles in facilities, resources and in skilled specialized investigators, 95% of therapies brought into product development by the pharmaceutical and biotechnology sector eventually fail, reflecting negative balance between efficacy and adverse effects.
Waldman, Scott A.; Hohl, R J.; Kearns, G L.; Swan, S J.; and Terzic, A, "Clinical pharmacology as a foundation for translational science." (2011). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 11.